ATM and myeloid sarcoma: Therefore, there is a requirement for potential-molecular markers to differentiate ATM from other demyelinating and inflammatory myelopathies, including MS, NMO, other systemic inflammatory diseases (SLE), acute disseminated encephalomyelitis, and postvaccinial myelitis [8].